Cargando…

Molecular Biomarkers and Histological Parameters Impact on Survival and Response to First- Line Systemic Therapy of Metastatic Colorectal Cancer Patients

BACKGROUND: Histological parameters of primary tumour and nodal metastases are prognostic factors for survival of operable colorectal (CRC) patients, but not predictive for response rate of systemic therapy. KRAS mutations in codons 12 and 13 were first recognized as a predictive factor for resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rebersek, Martina, Mesti, Tanja, Boc, Marko, Ocvirk, Janja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411021/ https://www.ncbi.nlm.nih.gov/pubmed/30840593 http://dx.doi.org/10.2478/raon-2019-0013

Ejemplares similares

The Five-year KRAS, NRAS and BRAF Analysis Results and Treatment Patterns in Daily Clinical Practice in Slovenia in 1(st) Line Treatment of Metastatic Colorectal (mCRC) Patients with RAS Wild-type Tumour (wtRAS) – A Real- Life Data Report 2013–2018
por: Mesti, Tanja, et al.
Publicado: (2023)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
por: Ocvirk, Janja, et al.
Publicado: (2016)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Retrospective Analysis of Treatment-naive Slovenian Patients with Metastatic Melanoma Treated with Pembrolizumab – Real-world Experience
por: Hribernik, Nezka, et al.
Publicado: (2020)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis
por: Rebersek, Martina, et al.
Publicado: (2011)

The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement
por: Mesti, Tanja, et al.
Publicado: (2015)

Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma
por: Moltara, Maja Ebert, et al.
Publicado: (2018)

Malignant gliomas: old and new systemic treatment approaches
por: Mesti, Tanja, et al.
Publicado: (2016)

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
por: Skof, Erik, et al.
Publicado: (2009)

Adverse Events During Immunotherapy in Slovenian Patients with Metastatic Melanoma Reveal a Positive Correlation with Better Treatment Outcomes
por: Mesti, Tanja, et al.
Publicado: (2021)

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
por: Mesti, Tanja, et al.
Publicado: (2022)

Consensus Molecular Subtypes (CMS) in Metastatic Colorectal Cancer - Personalized Medicine Decision
por: Rebersek, Martina
Publicado: (2020)

Metabolic Impact of Anti-Angiogenic Agents on U87 Glioma Cells
por: Mesti, Tanja, et al.
Publicado: (2014)

Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report
por: Kiraly, Peter, et al.
Publicado: (2022)

The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
por: Erman, Ana, et al.
Publicado: (2023)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Nuclear Magnetic Resonance Metabolic Fingerprint of Bevacizumab in Mutant IDH1 Glioma Cells
por: Mesti, Tanja, et al.
Publicado: (2018)

Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream
por: Ocvirk, Janja
Publicado: (2010)

Gut microbiome and its role in colorectal cancer
por: Rebersek, Martina
Publicado: (2021)

The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer
por: Oblak, Irena, et al.
Publicado: (2013)

Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study
por: Conde, Elisa, et al.
Publicado: (2021)

Impact of Perioperative Treatment on Survival of Resectable Gastric Cancer Patients After D2 Lymphadenectomy: A Single European Centre Propensity Score Matching Analysis
por: Jagric, Tomaz, et al.
Publicado: (2019)

Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting
por: Riedl, Jakob Michael, et al.
Publicado: (2017)

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
por: Saberzadeh-Ardestani, Bahar, et al.
Publicado: (2023)

Optimizing the first-line treatment for metastatic colorectal cancer
por: Cherri, Sara, et al.
Publicado: (2023)

The role of biomarker in later-line treatment for metastatic colorectal cancer
por: Kawakami, Takeshi, et al.
Publicado: (2023)

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
por: Aparicio, Jorge, et al.
Publicado: (2020)

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
por: Pander, Jan, et al.
Publicado: (2015)

First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
por: Numakura, Kazuyuki, et al.
Publicado: (2020)

The Use of High-frequency Short Bipolar Pulses in Cisplatin Electrochemotherapy in Vitro
por: Scuderi, Maria, et al.
Publicado: (2019)

Histology of metastatic colorectal cancer in a lymph node
por: Yokoyama, Shozo, et al.
Publicado: (2023)

Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study
por: Marschner, Norbert, et al.
Publicado: (2015)

Cetuximab in preoperative treatment of rectal cancer – term outcome of the XERT trial
por: Velenik, Vaneja, et al.
Publicado: (2012)

Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy
por: Jiang, Jinling, et al.
Publicado: (2019)

Short microsecond pulses achieve homogeneous electroporation of elongated biological cells irrespective of their orientation in electric field
por: Dermol-Černe, Janja, et al.
Publicado: (2020)

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy
por: Catalano, V, et al.
Publicado: (2009)

Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study
por: Hribernik, Nežka, et al.
Publicado: (2021)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_6b4naukkmbm9r2ekaoo0c2o5e1